Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/10/2025

Antiplatelet Therapy with Cangrelor

Introduction to Cangrelor

  • Cangrelor is a direct-acting, intravenous P2Y12 receptor antagonist with a rapid onset of action, potent platelet inhibition, and an extremely short half-life of 3-5 minutes, allowing platelet function to return to normal within 60 minutes after infusion discontinuation, as noted by the American College of Cardiology and the American Heart Association 1, 2

Pharmacological Properties

  • Cangrelor has a unique chemical structure as an adenosine triphosphate (ATP) analog, selectively, directly, and reversibly binding to the platelet P2Y12 receptor, blocking ADP-mediated platelet activation and aggregation without requiring metabolic activation, according to the American College of Chest Physicians 2
  • It is rapidly inactivated by dephosphorylation to a nucleoside with negligible antiplatelet activity and has an extremely short half-life of 3-5 minutes 2

Dosing and Efficacy

  • The standard FDA-approved dosing of cangrelor (30 μg/kg bolus followed by 4 μg/kg/min infusion) provides profound platelet inhibition, with a clear dose-response relationship with platelet function, as recommended by the American College of Cardiology 1, 3
  • Higher doses of cangrelor provide stronger protection against thrombotic events but increase bleeding risk, while lower doses improve platelet function, potentially reducing bleeding risk while still providing some antithrombotic effect, according to the American Heart Association 1, 3

Clinical Considerations

  • Cangrelor's short half-life allows for rapid recovery of platelet function regardless of dose, making it particularly useful in situations requiring rapid reversal of platelet inhibition, such as bleeding complications 2
  • Its parenteral administration overcomes limitations of oral P2Y12 inhibitors in situations with impaired absorption, NPO status, vomiting, or altered consciousness 2

Transition to Oral Therapy

  • Cangrelor binding to P2Y12 prevents the binding of active metabolites of thienopyridines (clopidogrel, prasugrel), complicating transitioning from cangrelor to oral thienopyridines, and oral P2Y12 inhibitors can only exert their effects once cangrelor dissociates from the receptor, as recommended by the European Society of Cardiology 2, 1, 3

Procedural Considerations

  • For procedures with high thrombotic risk, such as complex PCI, standard dosing of cangrelor may be preferred, as suggested by the American College of Cardiology, to balance thrombosis and bleeding risks 1, 3